Patents Assigned to Mydecine Innovations Group Inc.
  • Aza-substituted psilocin analogs and methods of synthesizing the same
    Patent number: 11952342
    Abstract: The present invention is directed to novel chemical compositions of matter and their methods of synthesis, and in particular novel analogs of Psilocin having enhanced physical and pharmacokinetic characteristics.
    Type: Grant
    Filed: May 1, 2023
    Date of Patent: April 9, 2024
    Assignee: Mydecine Innovations Group Inc.
    Inventors: Denton W. Hoyer, Robert F. Roscow
  • Aza-substituted psilocin analogs and methods of synthesizing the same
    Patent number: 11939292
    Abstract: The present invention is directed to novel chemical compositions of matter and their methods of synthesis, and in particular novel analogs of Psilocin having enhanced physical and pharmacokinetic characteristics.
    Type: Grant
    Filed: November 1, 2023
    Date of Patent: March 26, 2024
    Assignee: Mydecine Innovations Group Inc.
    Inventors: Denton W. Hoyer, Robert F. Roscow
  • Short-acting psychoactive compounds of the MDMA class
    Patent number: 11896577
    Abstract: The present invention is directed to novel chemical compositions of matter, and in particular novel MDMA class of compounds having substituted methylenedioxyphenethylamine and substituted amphetamine, having a metabolically labile thioether group.
    Type: Grant
    Filed: June 13, 2023
    Date of Patent: February 13, 2024
    Assignee: Mydecine Innovations Group Inc.
    Inventors: Denton W. Hoyer, Robert F. Roscow, Rong Ling, Chuanjun Gao